AN2 Therapeutics Inc Dossier - Source-backed chat

AN2 Therapeutics Inc

ANTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-0.33

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $5.32Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $200.8M

Enterprise Value $156.4M

Shares Outstanding 39.5M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

AN2 Therapeutics is a clinical-stage biopharmaceutical company leveraging its proprietary boron chemistry platform to develop novel small-molecule therapeutics. Following the strategic pivot away from its previously terminated Phase 3 EBO-301 study, the company has successfully diversified its pipeline. It is now advancing three distinct Phase 2-ready programs: oral epetraborole for polycythemia vera (PV), an investigator-initiated Phase 2 trial of epetraborole in Mycobacterium abscessus lung disease, and oral AN2-502998 for chronic Chagas disease. Bolstered by a $40.0 million private placement in March 2026, the company's cash runway extends into 2029, providing a solid financial foundation. However, because the company is pre-revenue and its primary value drivers are in early-to-mid-stage clinical development, a Hold recommendation is warranted until initial Phase 2 safety and efficacy readouts emerge.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$9.00

High · most bullish analyst$9.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company experiences clinical delays or safety signals in its upcoming Phase 2 trials, or the investigator-initiated trial in M. abscessus fails to show comparable efficacy to standard IV regimens. Elevated R&D expenses accelerate cash burn, shortening the projected runway and forcing dilutive financing before key milestones are achieved.

Base CaseCentral scenario

The company successfully initiates its planned Phase 2 trials in polycythemia vera and chronic Chagas disease by the end of 2026. Early safety and biomarker data from these trials, alongside progress in the investigator-initiated M. abscessus study, validate the boron chemistry platform. The cash runway remains highly stable, extending into 2029, which minimizes near-term dilution risk and supports a gradual recovery in valuation.

Bull CaseUpside scenario

The primary bull case centers on epetraborole's potential to become the first oral drug to control hematocrit in patients with polycythemia vera (PV), which would eliminate the need for frequent, burdensome phlebotomies and toxic cytoreductive therapies. Epetraborole has already demonstrated consistent hematocrit reduction in primates and non-PV individuals, alongside a strong tolerability profile. With a Phase 2 study in phlebotomy-dependent PV patients enrolling in Q3 2026 and initial safety data expected in Q4 2026, successful clinical readouts could unlock a massive market opportunity, as current PV therapies generate between $500 million and $1 billion in sales.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated boron chemistry platform with potential to deliver first-in-class and best-in-class small molecule therapeutics.
Strong balance sheet with $85.3 million in cash, cash equivalents, and investments as of March 31, 2026, extending the operational runway into 2029.
Diversified clinical pipeline with three active or planned Phase 2 programs spanning hematology, infectious diseases, and global health.
Strategic collaborations, including a research agreement with GSK targeting tuberculosis and a clinical development partnership with DNDi for Chagas disease.

Key Investment Risks

High clinical development risk inherent to early-and-mid-stage biopharmaceutical programs.
Pre-revenue status with ongoing quarterly net losses (~$10.0 million per quarter).
Binary outcomes of upcoming Phase 2 clinical readouts which will heavily dictate stock performance.
Dependence on a single core technology platform (boron chemistry) for the entire pipeline.

Thesis Invalidation Triggers

Failure to initiate the Phase 2 trial in polycythemia vera in Q3 2026 or the Phase 2 trial in chronic Chagas disease in late 2026.
Unexpected safety or tolerability issues emerging from the sentinel safety cohorts of the epetraborole PV study.
A significant increase in quarterly cash burn that materially shortens the projected runway into 2029.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.